glycopyrronium + indacaterol maleate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
glycopyrronium + indacaterol maleate: clinical details
Prescribing considerations
- Confirm COPD and that maintenance dual bronchodilation is intended; this product is not for acute bronchospasm or asthma.
- Assess whether the patient can correctly load, pierce and inhale from the capsule device.
- Avoid duplication with another LABA or LAMA.
- Use only after benefit–risk assessment in severe renal impairment or end-stage renal disease; use caution in severe hepatic impairment.
- Review cardiovascular disease, QT risk, diabetes, thyrotoxicosis, seizure disorders, narrow-angle glaucoma and urinary retention risk.
- The formulation contains lactose and is unsuitable in specified rare hereditary disorders of galactose metabolism.
Contraindications and cautions
- Hypersensitivity to indacaterol, glycopyrronium or an excipient.
Monitoring
- Check inhaler technique, adherence, symptom response and rescue-inhaler use.
- Monitor closely for anticholinergic effects in severe renal impairment.
- Assess pulse, blood pressure, rhythm or ECG when cardiovascular symptoms or relevant risk factors warrant it.
- Monitor blood glucose more closely when treatment starts in people with diabetes.
- Consider potassium assessment where hypoxia, severe COPD or interacting treatments increase hypokalaemia risk.
- Ask about eye pain, visual change and difficulty passing urine.
Clinical pharmacology
Indacaterol is a long-acting beta2-adrenoceptor agonist that raises intracellular cyclic AMP and relaxes bronchial smooth muscle. Glycopyrronium is a high-affinity muscarinic antagonist with functional activity at airway M3 receptors. Their complementary actions produce additive bronchodilation.
Formulation and product differences
- The product is a dry-powder hard capsule for inhalation through its dedicated Breezhaler device, not an oral capsule.
- Capsules contain lactose monohydrate and magnesium stearate and must remain protected from moisture in the blister until use.
- The inhaler supplied with each pack should replace the previous device.
glycopyrronium + indacaterol maleate interactions
Check all medicines, including eye drops and other inhalers, before prescribing or supplying.
Other long-acting beta2 agonists or long-acting muscarinic antagonists
Concurrent use is not recommended because it duplicates the medicine classes and may increase adverse effects.
Beta blockers, including ophthalmic preparations
They may reduce bronchodilation or provoke bronchospasm. If essential, a cardioselective option is generally preferred with caution.
Other anticholinergic medicines
Combined use has not been studied and may increase effects such as dry mouth, glaucoma or urinary retention.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.